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Abstract 
Effective vaccines against tuberculosis (TB) are needed in order to prevent TB transmission in human and animal 
populations. Evaluation of TB vaccines may be facilitated by using reliable animal models that mimic host pathophysi‑
ology and natural transmission of the disease as closely as possible. In this study, we evaluated the immunogenic‑
ity and efficacy of two attenuated vaccines, BCG and MTBVAC, after each was given to 17 goats (2 months old) and 
then exposed for 9 months to goats infected with M. caprae. In general, MTBVAC‑vaccinated goats showed higher 
interferon‑gamma release than BCG vaccinated goats in response to bovine protein purified derivative and ESAT‑6/
CFP‑10 antigens and the response was significantly higher than that observed in the control group until challenge. 
All animals showed lesions consistent with TB at the end of the study. Goats that received either vaccine showed 
significantly lower scores for pulmonary lymph nodes and total lesions than unvaccinated controls. Both MTBVAC and 
BCG vaccines proved to be immunogenic and effective in reducing severity of TB pathology caused by M. caprae. Our 
model system of natural TB transmission may be useful for evaluating and optimizing vaccines.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Tuberculosis (TB) is a multi-host zoonotic disease that 
affects a wide range of domestic and wild animals. TB 
in animals is caused by members of the Mycobacterium 
tuberculosis complex (MTBC), principally M. bovis and 
M. caprae. Consumption of raw milk and close con-
tact with infected animals are the most common routes 
of transmission to humans [1]. TB causes public health 
problems as well as economic losses for the livestock sec-
tor, which arise because of production losses and trade 
restrictions. It is, therefore, of paramount importance 
to prevent the development of advanced lesions that can 
result in an increased aerosol transmission between ani-
mals or between animals and humans, such as farmers, 
abattoir workers or veterinarians.
Policies to check for TB in animals focus on testing 
and slaughtering reactor cattle [2, 3]. However, routine 
diagnostic tests and compensation for slaughter are una-
vailable in many countries, making cost-effective alter-
natives such as vaccination of great interest. Vaccination 
should target not only immediate animal hosts but also 
other domestic and wild hosts that can help maintain 
the disease [4] such as goats or wild animals, which help 
maintain TB in cattle [5]. Combining vaccination with 
eradication programs requires TB diagnostic tests that 
can differentiate between infected and vaccinated ani-
mals (DIVA strategy) and that have a sensitivity as high 
as the current official diagnostic tests based on protein 
purified derivative (PPD) [6]. At present, cattle vaccina-
tion is forbidden in the European Union (Chapter III, 
Article 13, Council Directive 78/52/EEC), and only the 
Bacille Calmette–Guérin (BCG) vaccine is licensed for 
use in badgers in the UK (Marketing authorisation Vm 
03326/4021).
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In humans, TB is caused mainly by M. tuberculosis and 
it is still the leading cause of death from a single infec-
tious agent. Moreover, drug-resistant TB is an increasing 
threat [7]. Thus, effective vaccines to prevent TB trans-
mission are urgently needed. BCG is the only vaccine 
licensed for use in humans. It can protect against menin-
geal and disseminated (extra-pulmonary) TB in children 
[8]. However, it shows variable efficacy in preventing 
pulmonary TB in adults [8, 9]. A promising potential 
alternative to BCG is MTBVAC, another attenuated 
M. tuberculosis vaccine that is in phase II clinical tri-
als in neonates (clinical trial identifier: NCT035336117) 
and adolescents (NCT02933281). Of the 13 TB vac-
cines currently in clinical trials, only MTBVAC con-
tains attenuated M. tuberculosis [7]. MTBVAC is based 
on two independent genetic deletions in the genes phoP 
and fadD26, which encode two major virulence factors 
and conserve genetic regions that encode important and 
immunodominant antigens absent from BCG [10]. In 
previous studies, the SO2 prototype vaccine (including 
only the phoP deletion) and subsequent MTBVAC vac-
cine proved to have greater immunogenicity and efficacy 
than BCG in mice [11–13], guinea pigs [11, 14] and rhe-
sus macaques [15]. SO2 conferred partial protection on 
goats naturally exposed to M. bovis and M. caprae but 
no results of efficacy using MTBVAC have been reported 
[16]. Goats are a suitable model for TB studies and it has 
been used in previous vaccination studies [17].
The main objective of the present study was to evalu-
ate, for the first time, the immunogenicity and protec-
tive efficacy of MTBVAC in goats naturally exposed to 
M. caprae. Of all species in the MTBC, M. caprae is the 
most frequent in goats. This study aimed to examine cel-
lular and humoral responses triggered by MTBVAC in 
goats, as well as the protection conferred by an attenu-
ated M. tuberculosis vaccine. The study also assessed pos-
sible interference from the MTBVAC vaccine in current 
TB diagnostic tests in animals using PPDs, ESAT-6, CFP-
10 or Rv3615c as antigens.
Materials and methods
Experimental design
Fifty-one Murciano–Granadina goat kids (8  weeks old) 
were selected from a farm in Spain with no history of 
TB that imposed strict biosecurity measures and raised 
kids artificially, producing animals of high genetic value. 
All goats were confirmed to be TB-negative using a com-
mercial interferon-gamma release assay (IGRA; Bovigam 
TB kit, Thermo Fisher Scientific, Waltham, USA) based 
on criteria recommended by the Spanish TB eradication 
program (Ministry of Agriculture, Fisheries and Food) 
for cattle and goats (see IGRA section below). The ani-
mals were distributed into three groups (Figure 1): BCG 
(n = 17), MTBVAC (n = 17) and control (n = 17).
The first two animal groups received, at 2  months of 
age, MTBVAC vaccine (0.1  mL, 5 × 105 colony forming 
Figure 1 Experimental design. Black goat silhouettes represent receptor goats (vaccinated and control groups), and white goat silhouettes 
represents the donor goats infected with M. caprae. 
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units; lot number 143072, Biofabri SL, Porriño, Spain) or 
BCG Danish SSI 1331 (2–8 × 105 colony-forming units; 
lot number L389336B, Statens Serum Institute, Copen-
hagen, Denmark). Vaccines were obtained as freeze-dried 
preparations and were reconstituted according to the 
manufacturers’ instructions in Sauton’s medium (BCG) 
or MTBVAC diluent (Biofabri, Porriño, Spain). Vaccines 
were administered subcutaneously into the medial area 
of the left-hand side of the neck using a needle 16  mm 
long. Control goat kids remained unvaccinated.
At 3 months post-vaccination, all three groups of goat 
kids were exposed to 30 reactor goats from an infected 
herd. The reactor goats were TB-positive based on IGRA 
and single intradermal tuberculin (SIT) tests, and the 
donor farm was confirmed to have TB caused by M. 
caprae spoligotype SB0157. Vaccinated and control goat 
kids cohabited with the reactor goats for 9  months in a 
biosafety facility. Animal handling, testing and sampling 
were performed by qualified veterinarians in accordance 
with European (86/609/CEE) and Spanish (RD 53/2013) 
legislation. All procedures were authorised by an insti-
tutional ethical committee and approved by the local 
authorities (PROEX: 411/15; Comunidad de Madrid).
IGRA 
Blood samples were collected immediately prior to vac-
cination (T0, where T# refers to how many months 
after vaccination), T1, T3 (exposure), T5, T7, T9, T11, 
and T12 (end point) (Table  1). Heparinised blood sam-
ples were stimulated as described [18] with bovine pro-
tein purified derivative (PPD-B) and avian PPD (PPD-A) 
(CZ Vaccines, Porriño, Spain) at a final concentration of 
Table 1 Number of positive reactors in each experimental group using different diagnostic tests and antigens 
E%, ELISA percentage for interpretation and cut-off point; E/C, cocktail of ESAT-6/CFP-10; IGRA, interferon-gamma release assay; NA, not available; PPD-B, bovine 
purified protein derivative; PPD-A, avian purified protein derivative; SIT, single intradermal tuberculin test; SCIT, single comparative intradermal tuberculin test.
a Vaccination (time in months).
b Exposure to infected animals.
c Cut-off 0.1.
Test Antigen Group T0a T1 T3b T5 T7 T9 T11 T12
IGRA PPD‑B cut‑off 0.05 Control 0/17 0/17 0/17 2/17 9/15 12/14 10/12 10/12
BCG 0/17 2/17 6/17 0/17 3/15 7/14 10/14 8/14
MTBVAC 0/17 14/17 7/17 1/16 5/15 11/13 11/13 12/13
PPD‑B cut‑off 0.1 Control 0/17 0/17 0/17 2/17 8/15 12/14 10/12 10/12
BCG 0/17 2/17 5/17 0/17 1/15 3/14 7/14 6/14
MTBVAC 0/17 12/17 4/17 0/16 3/15 8/13 6/13 9/13
E/Cc Control 0/17 0/17 NA 2/17 5/15 11/14 6/12 7/12
BCG 0/17 0/17 NA 0/17 0/15 0/14 2/14 1/14
MTBVAC 0/17 3/17 NA 1/16 0/15 4/13 1/13 5/13
Rv3615c Control 0/17 0/17 NA 1/17 3/15 8/14 3/12 3/12
BCG 0/17 0/17 NA 0/17 0/15 0/14 0/14 0/14
MTBVAC 0/17 1/17 NA 0/16 0/15 1/13 1/13 3/13
SIT test PPD‑B Control NA NA 1/17 2/17 NA 11/14 NA 11/12
BCG NA NA 15/17 4/17 NA 2/14 NA 11/14
MTBVAC NA NA 15/17 1/16 NA 8/13 NA 12/13
E/C Control NA NA NA 2/17 NA 9/14 NA 6/12
BCG NA NA NA 1/17 NA 2/14 NA 2/14
MTBVAC NA NA NA 0/16 NA 5/13 NA 5/13
SCIT test PPD‑B and PPD‑A Control NA NA 0/17 2/17 NA 7/14 NA 10/12
BCG NA NA 10/17 1/17 NA 1/14 NA 8/14
MTBVAC NA NA 11/17 0/16 NA 6/13 NA 9/13
P22_ELISA (E% 100) P22 and PPD‑A Control 0/17 0/17 0/17 0/17 3/15 2/14 8/12 6/12
BCG 0/17 0/17 0/17 3/17 5/15 2/14 11/14 13/14
MTBVAC 0/17 1/17 0/17 3/16 8/15 1/13 12/13 10/13
P22_ELISA (E% 150) P22 and PPD‑A Control 0/17 0/17 0/17 0/17 2/15 2/14 4/12 6/12
BCG 0/17 0/17 0/17 2/17 2/15 1/14 4/14 5/14
MTBVAC 0/17 1/17 0/17 0/16 3/15 0/13 4/13 8/13
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20 µg/mL, along with the peptide cocktail ESAT6/CFP10 
(E/C) and peptide Rv3615c (provided by the Animal and 
Plant Health Agency, Addlestone, UK); both peptides 
were given at a final concentration of 5 μg/mL. IFN-γ lev-
els in plasma were measured using a commercial IGRA 
(Bovigam TB kit). Animals were considered to be posi-
tive when the optical density (OD) of a sample stimulated 
with PPD-B, after subtracting the OD of phosphate-buff-
ered saline (PBS), was ≥ 0.05 and greater than the OD 
of the sample stimulated with PPD-A. A less stringent 
threshold of 0.1 was applied when samples were stimu-
lated with PPD-A or the E/C peptide cocktail and peptide 
Rv3615c. Results for the E/C peptide cocktail and peptide 
Rv3615c were interpreted separately from each other and 
without taking into account the OD for samples stimu-
lated with PPD-A [16, 18].
Intradermal tuberculin tests
Vaccinated and control goats were subjected to a SIT 
test and a single comparative intradermal tuberculin 
(SCIT) test at T3 (exposure), T5, T9 and T12. Both tests 
were performed according to Council Directive 64/432/
EEC and Royal Decree RD2611/1996. PPD-B and PPD-A 
(0.1 mL; CZ Vaccines, Porriño, Spain) were inoculated on 
the left-medial or right-medial side of the neck, respec-
tively. The test was interpreted for all animals by the 
same veterinarian 72 h later. The SIT test was considered 
positive when skin fold thickness increased by ≥ 4  mm 
or clinical signs (exudation, oedema or necrosis) were 
detected. The SCIT test was considered positive when 
the bovine reaction was larger than the avian reaction by 
more than 4 mm or clinical signs were observed at the 
bovine site. The animals were inoculated with a cocktail 
of ESAT-6 and CFP-10 proteins (E/C, 100 μg/mL; Lionex, 
Braunschweig, Germany) at T5, T9 and T12. The intra-
dermal E/C test results were interpreted in the same way 
as the SIT test results.
Serology
An in-house competitive P22 ELISA, which measures 
immunoreactivity against a protein P22 affinity-puri-
fied from bovine PPD (CZ Vaccines, Porriño, Spain), 
was performed at T0, T1, T3, T5, T7, T9, T11 and T12 
as described elsewhere [19]. Briefly, assay plates were 
coated overnight at 4  °C with 50 μL of P22 at 10  μg/
mL, blocked with 5% skimmed milk powder solution in 
phosphate-buffered saline (PBS) for 1  h at room tem-
perature, and washed three times with PBS containing 
0.05% Tween-20 (PBST). Sera were diluted 1:100 in skim 
milk and supplemented with avian PPD at 150  μg/mL, 
then added in duplicate the wells. Plates were incubated 
for 60 min at 37  °C. Horseradish peroxidase-conjugated 
rabbit anti-sheep IgG (H + L, diluted 1:2000, 100 μL; 
SouthernBiotech, Birmingham, USA) was added, and 
plates were incubated for 30  min at room temperature. 
Plates were washed five times with PBST, and color was 
developed by adding 100 μL of o-phenylenediaminedi-
hydrochloride substrate (FAST OPD, Sigma-Aldrich, 
St. Louis, USA) and incubated for 15  min in darkness 
at room temperature. The reaction was stopped with 
50 μL of 3 N  H2SO4. OD at 492 nm was measured with 
an ELISA reader. Negative control serum was obtained 
from TB-free goats that were negative for MTBC culture; 
positive control serum was obtained from goats positive 
for MTBC culture. Positive and negative controls were 
included in every plate in quadruplicate. ELISA results 
were expressed as an ELISA percentage (E%) = [mean 
sample OD/(2 ×  mean of negative control OD)] ×  100. 
The cut-off value was defined as the ratio of the mean 
sample OD to the double of the mean OD of the nega-
tive control. Serum samples with E% values greater than 
100 were considered positive. A less stringent cut-off of 
E% ≥ 150 was also applied [19].
Environmental sampling
The environmental circulation of mycobacteria within 
the herd and their presence on the body surface of the 
vaccinated and control groups were evaluated by scrub-
bing the animals’ skin at T3, T5 and T12 with pre-
hydrated sponges containing 15  mL of a liquid solution 
(patent pending). Animals were scrubbed 10 times on 
both sides of the dorsolateral thorax and abdomen. The 
fluid was then recovered from the sponge, re-diluted by 
addition of 10 mL and centrifuged at 1500 g for 10 min. 
The DNA was extracted using a  DNeasy® Blood & Tis-
sue kit (Qiagen, Hilden, Germany), then used as template 
in quantitative PCR amplification of the IS6110 sequence 
[20].
Gross lesions and histopathology
At 9  months after exposure and 12  months after vac-
cination (T12), the receptor and donor animals were 
sedated by means of an intravenous injection of xyla-
zine at 10 mg/50 kg (2% Xilagesic, Calier SA, Barcelona, 
Spain), and then euthanized with an intravenous injec-
tion of T-61 (MSD Animal Health, Salamanca, Spain). 
The thoracic perimeter was measured (in cm), and differ-
ences among groups as well as the association with tho-
rax pathology were analysed. Gross lesions on all organs 
were systematically examined using two semi-quantita-
tive systems, one for the lungs and another for the lymph 
nodes (LNs) and remaining organs. Gross lesions in the 
lung lobes were categorised in five groups according to 
the percentage of the lobe affected: 0 or no evident TB-
compatible lesions (TBCL); 1, under 25% of the lung lobe 
affected; 2, 25–50%; 3, 50–75%; and 4, > 75%. One extra 
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point was given to animals that had pleural adhesions. 
The total lung score was the sum of the scores for each 
lung lobe (left apical, left diaphragmatic, right apical, 
right cardiac, right accessory and right diaphragmatic). 
The size and number of lesions were scored across six 
categories as described [21] in retropharyngeal LNs, 
pulmonary LNs (left and right tracheobronchial, and 
mediastinal), hepatic LN, ileocecal LN and mesenteric 
LNs. Lesions were also scored in other organs contain-
ing TBCLs. The following scoring system was applied: 0, 
no visible lesions; 1, no gross lesions but lesions appar-
ent on slicing; 2, ≤ 5 gross lesions < 10  mm in diame-
ter; 3, ≥ 6 gross lesions < 10  mm in diameter or a single 
gross lesion > 10  mm in diameter; 4, > 1 distinct gross 
lesion > 10  mm in diameter; 5, coalescing gross lesions. 
The pulmonary LN score was the sum of the scores for 
the left and right tracheobronchial as well as mediastinal 
LNs. The pulmonary LN score and extra-pulmonary LN 
scores and total lung scores were added up to determine 
the total score per animal. The personnel in charge of 
the necropsies were blinded to the identity of the group 
of vaccinated animals examined, and the same assessor 
scored all animals in order to ensure scoring consistency.
Tissue samples were fixed in 10% phosphate-buffered 
formalin for 48 h before being embedded in paraffin wax. 
Four-micron sections were cut and stained with hema-
toxylin and eosin (H&E). Histopathology analysis was 
carried out by examining three microscopic fields (40×) 
from a section of 1 × 1  cm of cranial and caudal medi-
astinal, left and right tracheobronchial LNs and lung in 
order to assess the quantity of multinucleated giant cells 
(MNGCs) and the number and stage of the granulomas 
(I–IV), where stage I is the initial; stage II, solid; stage III, 
minimal necrosis; and stage IV, necrosis and mineralisa-
tion [22]. The presence of small satellite granulomas sur-
rounding a central lesion [23] was also recorded.
Bacteriology
The tissue samples comprised head and thorax tis-
sues obtained from the retropharyngeal, mediastinal 
and bronchial LNs and lungs. The samples were decon-
taminated with 0.37% hexadecylpyridinium chloride 
[24], and then cultured on Coletsos and 0.2% (w/v) 
pyruvate-enriched Löwenstein–Jensen media (Difco, 
Madrid, Spain). Isolates were identified as MTBC using 
conventional PCR and/or DVR-spoligotyping [25]. The 
head and thorax tissue samples were cultured in paral-
lel on Columbia Agar media plates with 5% of sheep’s 
blood (BioMèrieux, Madrid, Spain) for the isolation of 
Corynebacterium pseudotuberculosis as described [16].
Bacterial DNA was quantified in 2-g pooled samples 
of respiratory LNs and lungs after 28 days of culturing in 
liquid medium (Bactec MGIT 960, Becton–Dickinson). 
DNA was extracted from 1.5 mL of liquid medium from 
positive samples. The medium was centrifuged at 9000 
g for 5  min, the supernatant was removed and the pel-
let was washed with sterile distilled  H2O, centrifuged 
again, suspended in 200 μL of water, and heat-inacti-
vated. Purity and concentration of DNA samples were 
measured using a NanoDrop 2000 spectophotometre 
(Thermo Fisher Scientific, Waltham, USA). Bacterial 
growth was quantified absolutely using qPCR targeting 
the mpb70 gene [26]. The standard DNA curve was gen-
erated using DNA extracted from a M. bovis AN5 culture 
by phenol:chloroform:isoamyl alcohol. DNA concentra-
tion was adjusted to 1.2 ng/μL (approximately 2.53 × 105 
copies/μL) and 12  fg/μL (2.53 copies/μL) using a Qubit 
4 fluorometer (Thermo Fisher Scientific). The number 
of copies of the mpb 70 gene was defined as equal to the 
number of bacteria, since MTBC species contain only 
one copy of this gene [26].
Statistical analyses
All tests were carried out using SPSS 25 (IBM, New York, 
USA), and a p value of 0.05 was defined as the cut-off for 
statistical significance. The confidence intervals for pro-
portions were calculated according to Wilson’s 95% inter-
vals. Normality of quantitative values was assessed using 
the Kolmogorov–Smirnov test. Fisher’s exact test was 
used to compare the proportions of positive test results 
between groups, as well as to assess homogeneity in the 
results for TBCL presence or absence and for infection 
prevalence. The Kruskal–Wallis test was used to compare 
quantitative results between groups, such as skin fold 
thickness, IFN-γ level, P22 ELISA OD, thoracic perim-
eter and lesion score; this test was followed by pairwise 
tests for multiple comparisons of mean rank sums after 
Bonferroni correction of the p value. Quantitative values 
were compared between different time points using the 
Wilcoxon signed-rank test. The Spearman’s rank corre-
lation coefficient (rho) was used to assess relationships 
among IFN-γ levels after stimulation with E/C and PPD-
B, the increase in skin fold thickness, the thoracic perim-
eter or P22 ELISA OD and the lesion score.
Results
Clinical signs and follow‑up
No clinical signs or adverse reactions were observed at 
the site of vaccine inoculation in any of the vaccinated 
animals. At the final time point, thoracic perimeter did 
not differ significantly among the groups (p = 0.157; 
median = 65.3  cm, interquartile range (IQR) 63.6–66.8; 
BCG, median = 67.8  cm, IQR 63.1–72.5; MTBVAC, 
median = 66.5 cm, IQR 63.3–68.5).
Three animals in the BCG group, four in the MTBVAC 
group and five in the control group died between T5 and 
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T11, corresponding to between 2 and 8  months post-
exposure. One goat without TBCL from the MTBVAC 
group and three control goats with TBCL were culture-
positive. None of the 8 remaining fatalities had either 
TBCL or positive culture. All 12 animals were excluded 
from the post-mortem analysis because the presence and 
severity of their lesions were not comparable to those of 
the animals slaughtered at the end point.
Immune response to vaccination and natural exposure
The numbers of reactors to the cellular and antibody-
based tests (IGRA, SIT, SCIT, P22 ELISA) are sum-
marised in Table  1. At T1, the MTBVAC group had a 
significantly greater number of reactors to the IGRA 
based on PPD-B (using 0.05 cut-off, 82.4%, 95% CI 
59–93.8; using 0.1 cut-off, 70.6%, 95% CI 46.8–86.7) 
than the BCG and control groups (p < 0.001). From T1 
to T3, the percentage of IGRA-positive animals (0.05 
cut-off) decreased in the MTBVAC group but increased 
in the BCG group, and both percentages remained sig-
nificantly higher than in the control group (p = 0.007 and 
p = 0.018, respectively). In all groups, IFN-γ response to 
PPD-B started to increase steadily from T7 to T12, corre-
sponding to 4 months after exposure until the end of the 
experiment. IFN-γ levels peaked at T9 in the MTBVAC 
and control groups, yet levels in the MTBVAC and BCG 
groups were significantly lower than in the control group 
(Figure  2A; p = 0.049 and p < 0.001, respectively). At the 
end of the study, the BCG group, but not the MTBVAC 
group, showed significantly lower IFN-γ levels than the 
control group (Figure 2A; p = 0.020).
Based on a 0.1 cut-off, three MTBVAC animals were 
positive for E/C at T1 (specificity = 82.35%, 95% CI 
58.97–93.81). At T7, neither vaccinated group contained 
animals positive for the IGRA based on E/C, a rate sig-
nificantly lower than in the control group (Table  1; 
both p = 0.042). However, by the final time point before 
necropsies, the MTBVAC group no longer differed signif-
icantly from the control group, while the BCG group did 
(Table  1; p = 0.009). After 4, 6 and 9  months in contact 
with infected donors (T7, T9 and T12), the BCG group, 
but not the MTBVAC group, showed significantly lower 
IFN-γ response to E/C than the control group (Figure 2B; 
T7, p = 0.001; T9, p < 0.001; T12, p = 0.010). At T12, 
IFN-γ levels in response to E/C when considering all the 
groups together showed a moderate, positive correlation 
with total lesion score (rho = 0.496, p < 0.01).
The proportion of IGRA-positive reactors among the 
infected ones in the control group at T12 increased from 
58.3% (95% CI 32–80.7) when only the E/C cocktail was 
used to 75% (95% CI 46.8–91.1) when the cocktail was 
used together with Rv3615c peptide. One additional 
animal was positive when PPD-B was used (83.3%, 95% 
CI 55.2–95.3). Rv3615c did not allow detection of any 
infected BCG animals, and it allowed detection of some 
infected MTBVAC animals (Table 1).
Before exposure (T3), both vaccinated groups showed 
higher reactivity on the SIT and SCIT tests using PPDs 
than the control group did (p < 0.001). At this time point, 
the increase in skin fold thickness after PPD-B inocula-
tion was higher for the two vaccinated groups than for 
the control group (both p < 0.001). Similar results were 
observed for T5 (p = 0.038 and p = 0.001, respectively). 
All three groups showed maximal increase in skin fold 
thickness at T9 as observed in the IGRA levels using 
PPD-B and E/C (Figure 2A and B), and at this time point, 
BCG goats showed a significantly smaller increase in skin 
fold thickness than control goats (p = 0.002).
Antibody levels against P22 increased over time 
from T3 to T12 (except T9) in all groups (Figure  3). 
Only one goat from the MTBVAC group had an 
Figure 2 Median and interquartile range of IFN‑γ (OD450nm) in 
blood samples after stimulation with PPD‑B (A) or E/C cocktail 
(B) in each animal group at different time points during the 
study. ***p < 0.001; **p < 0.01; *p < 0.05.
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antibody titre over the cut-off point after vaccination 
(T1) and before exposure. At T5, the median E% value 
was higher in the BCG group than in the control group 
(p = 0.003) and MTBVAC group (p = 0.043). At T7, the 
median E% was significantly higher in the MTBVAC 
group than in the control group (p = 0.032). At the end 
point (T12), only 50% (95% CI 25.4–74.6) of control 
goats were positive in the P22 ELISA according to both 
cut-offs (Table  1). However, 13/14 of the BCG-vacci-
nated goats and 10/13 of MTBVAC-vaccinated goats 
were positive according to the stringent cut-off. No 
correlation was observed between the E% and the total 
lesion score at T12 when considering all the groups 
together (rho = − 0.31, p = 0.851) or when consider-
ing only the control group (rho = 0.218, p = 0.494). The 
intradermal tests may have affected the antibody lev-
els in all groups, since E% values for the intradermal 
tests increased significantly from T3 to T5 in all the 
groups (BCG, p = 0.002; MTBVAC, p = 0.003; control, 
p = 0.049), as well as from T9 to T11 (BCG, p = 0.001; 
MTBVAC, p = 0.003; control, p = 0.003).
Environmental DNA
At 2  months post-exposure (T5), the rate of MTBC 
identification was 82% of the samples (41/50, 95% 
CI 69.2–90.2), without significant differences 
among groups (control = 13/17, BCG = 16/17, MTB-
VAC = 12/16). Seven  months later (T12), all sponge 
samples were positive for MTBC (39/39, 100%, 95% CI 
91.0–100).
Post‑mortem examination
TBCLs were observed in the lungs or pulmonary LNs of 
all animals. There were lesions in 93.3% (95% CI 78.7–
98.2) of donor goats, all of which died during the study 
or were euthanized at the end point. BCG and MTBVAC-
vaccinated goats showed significantly lower pulmonary 
LN scores than controls (p < 0.001 and p = 0.005, respec-
tively) as well as lower total lesion scores (p = 0.001 and 
p = 0.032, respectively) (Figure  4A and D). The BCG 
group, but not the MTBVAC group, showed significantly 
lower lung lesion score than the control group (p = 0.028; 
Figure 4B). The BCG group, but not the MTBVAC group, 
also showed a significantly lower median number of 
affected lung lobes than the control group (Table 2). The 
most affected lobes in all groups were the caudal ones: 
gross lesions in the right caudal lobe were most preva-
lent in control goats (10/12) and BCG goats (5/14), while 
gross lesions in the left caudal lobe were most preva-
lent in MTBVAC goats (10/13). No extra-pulmonary 
lesions were observed in 8 goats vaccinated with BCG 
(57.1%, 95% CI 32.6–78.6) and 9 vaccinated with MTB-
VAC (69.2%, 95% CI 42.4–87.3), compared to only 3 con-
trols (8.3%, 95% 1.5–35.4) (BCG, p = 0.130; MTBVAC, 
p = 0.047). Extra-pulmonary lesion scores in the control 
group were similar to those in the BCG group (p = 0.181) 
and MTBVAC group (p = 0.051) (Figure 4C). 
Table 2 presents the histopathology findings. Stage IV 
was the stage of granuloma most frequently observed 
in the lungs and pulmonary LNs of all groups. These 
lesions were characterised by a central necrosis with 
mineralisation surrounded by a granulomatous inflam-
matory response. Macrophages and epitheloid cells were 
aggregated around the necrotic lesions, forming Langer-
hans giant cells, and were significantly fewer in the lungs 
and pulmonary LNs of the BCG group than in the other 
groups (Table  2). Similar proportions of animals in all 
three groups showed satellite granulomas in their lungs 
and pulmonary LNs.
Bacteriology
The isolation rate was 12/12 (100%, 95% CI 75.8–100) in 
the control group, 8/14 (57.1%, 95% CI 32.6–78.6) in the 
BCG group and 11/13 (84.6%, 95% CI 57.8–95.7) in the 
MTBVAC group (BCG, p = 0.017; MTBVAC, p = 0.48). 
The only spoligotype identified was M. caprae SB0157. 
Moreover, two animals from the control and MTB-
VAC groups were co-infected with Corynebacterium 
pseudotuberculosis/M. caprae, and C. pseudotuberculosis 
alone was isolated from one goat vaccinated with BCG. 
The isolation rate in donor goats was 80% (95% CI 62.7–
90.5); donor animals did not undergo the detailed nec-
ropsy of receptor goats.
Figure 3 Median and interquartile range of the ELISA 
percentage (E%) observed in the P22 ELISA in each group at 
different time points during the study. Intradermal tests (ITs) were 
performed at T3, T5, T9 and T12 (black arrows). ***p < 0.001; **p < 0.01; 
*p < 0.05.
Page 8 of 13Roy et al. Vet Res           (2019) 50:82 
Quantitative PCR indicated similar bacterial DNA lev-
els in respiratory LNs and lungs across the groups. The 
median value was 5.2 × 104 bacteria/μL (IQR, 4.2 × 104–
7.5 × 104) in the BCG group, 1.03 × 105 bacteria/μL 
(IQR 3.4 × 104–12.8 × 104) in the MTBVAC group, and 
6.8 × 104 bacteria/μL (IQR 4.2 × 104–9.2 × 104) in the 
control group.
Discussion
In the present study, BCG and MTBVAC vaccines led to 
milder gross TB pathology under conditions of long-term 
exposure to M. caprae. MTBVAC effectively reduced 
the frequency of animals with extra-pulmonary TB 
and severity of TBCLs in pulmonary LNs, while BCG 
reduced the pathology severity in lungs and pulmonary 
LNs. For 9  months, vaccinated and control goats were 
in constant direct contact, via aerosols, with infected 
goats, and they shared feed and water points, providing 
a natural transmission model similar to that described for 
goats vaccinated with the M. tuberculosis SO2 strain [16]. 
Natural transmission models can be a particularly reli-
able method to evaluate vaccines, treatments and diag-
nostic tests for animals or humans, but they also have 
disadvantages, including high maintenance costs and 
the impossibility of knowing infection dates or exposure 
doses. Therefore, the development of new biomarkers 
correlated with disease progression would be valuable to 
reliably set end points in field and laboratory trials.
Environmental sampling confirmed the continu-
ous exposure in our natural transmission model, since 
MTBC was detected in 82% of samples at 2  months 
post-exposure (T5). This innovative technique is easy to 
perform and useful as a surveillance tool for the analy-
sis of environmental bacterial load and potential risk of 
exposure not only in the case of TB but other infections 
as well. The high bacterial load and persistent exposure 
Figure 4 Lesion scores in pulmonary lymph nodes (LNs) (A), lungs (B), extra‑pulmonary organs (C) and in all organs examined (D) in the 
control, BCG and MTBVAC groups. Horizontal lines represents median values. ***p < 0.001; **p < 0.01; *p < 0.05; †p < 0.1.
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on the farm may have predisposed all goats to develop 
visible TB lesions and high culture positivity. Transmis-
sion may also have been promoted by the fact that goats 
are the natural hosts of M. caprae, the SB0157 spoligo-
type is the most frequent M. caprae strain isolated from 
cattle in Spain [27], and SB0157 is associated with severe 
TB in Eurasian wild boar [28]. A similar study evaluating 
the SO2 prototype of MTBVAC in goats that were kept 
in contact with donors infected with M. bovis (SB0134 
and SB0339) and M. caprae (SB0157) found that the pro-
totype led to 63.6% lower mean total lesion scores and 
89.5% lower lung lesion scores than in unvaccinated goats 
[16]. In the present study, we introduced animals from 
only one origin infected with M. caprae SB0157, and the 
MTBVAC led to 57% lower mean total lesion scores and 
34.1% lower lung lesion scores than in controls. Severity 
of gross lesions was similar between the BCG and MTB-
VAC groups. In our earlier work, we found that the SO2 
vaccine led to lower lesion scores and lower proportion 
of bacteriology isolation than BCG, although imbalance 
between the sizes of the BCG and SO2 groups prevented 
definitive conclusions [16]. The period of exposure was 
similar in that previous study using the SO2 vaccine and 
the present study but other factors could be responsi-
ble for the different reduced gross pathology observed 
between studies. One of the factors may be the lower 
ratio of donors/vaccinated goats in the SO2 study com-
pared to the present one. Another point to take into con-
sideration is the MTBC species and strain, since in the 
present study, vaccinated goats were exposed to a group 
of infected donors with one M. caprae strain throughout 
the study, whereas in the previous SO2 study, vaccinated 
goats were first exposed to infected donors with two M. 
bovis strains for 18  weeks and then to infected donors 
with a single M. caprae strain the following 22  weeks. 
Therefore, the virulence of the MTBC species and strains 
in goats might also have played an important role in the 
differences in lesion severity as suggested by Bezos et al. 
[29].
In the present study, the rate of bacteriological isolation 
in the thorax was lower in the BCG group than in the 
control group. Nevertheless, no differences were found in 
the quantification of bacterial DNA from the lungs and 
pulmonary LNs samples across all three groups. Lesion 
grade here did not correlate with bacterial load, in con-
trast to what has previously been described in goats [23, 
Table 2 Gross and histopathological analysis of TBL in lung and pulmonary lymphoid nodes 
IQR, interquartile range; MNGC, multinucleated giant cells; TBL, tuberculous lesion.
* Statistically significant difference with regard to the control group (p ≤ 0.05).
a MNGCs per animal (mean of three microscopic fields 400×).
b Lung and pulmonary samples from one animal were not well fixed in formalin and could not be assessed for histopathology.
Control BCG MTBVAC
Lung
 Median no. of lobes affected 3.5 (IQR 1–4) 1 (IQR 0.8–1)* 2 (IQR 1–2.5)
 Median score 4 (IQR 1–5.8) 1 (IQR 0.8–1.3)* 2 (IQR 1–4)
 No. animals with TBL 10/11 (83.3%)b 3/14 (21.4%)* 8/13 (61.5%)
 Development stage of granulomas
  I 0/11 (0%) 0/14 (0%) 0/13 (0%)
  II 1/11 (9.1%) 0/14 (0%) 3/13 (23.1%)
  III 2/11 (18.2%) 0/14 (0%) 0/13 (0%)
  IV 7/11 (63.6%) 3/14 (21.4%)* 5/13 (38.5%)
 Mean of  MNGCsa 7 (± 8.1) 1.6 (± 3.7)* 5.1 (± 8)
 No. animals with satellite granulomas 0/11 (0%) 1/14 (7.1%) 0/13 (0%)
Pulmonary LNs
 Median score 6.5 (IQR 4.3–9.8) 2 (IQR 1–3.3)* 2 (IQR 2–4)*
 No. animals with TBL 11/11 (100%)b 8/14 (57.1%)* 10/13 (76.9%)
 Development stage of granulomas
  I 0/11 (0%) 0/14 (0%) 1/13 (7.7%)
  II 1/11 (9.1%) 0/14 (0%) 0/13 (0%)
  III 1/11 (9.1%) 0/14 (0%) 0/13 (0%)
  IV 9/11 (81.8%) 8/14 (57.1%) 9/13 (69.2%)
 Mean of MNGCs 10.7 (± 6.9) 3.71 (± 5.52)* 9.1 (± 11.7)
 No. animals with satellite granulomas 5/11 (45.5%) 1/14 (7.1%) 4/13 (30.8%)
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30] and nonhuman primates [31, 32]. The higher bacte-
rial load could also be related to the type of the lesions 
(cavitary vs granulomatous) [17], but we could not dis-
criminate between different lesions in this study since 
samples from different tissues were pooled. Histopatho-
logical analysis revealed that most animals had Stage IV 
granulomas in the lung and pulmonary LNs, and its pro-
portion in lungs was significantly lower in the BCG group 
than in the control group. The BCG group also showed 
significantly lower mean MNGCs per group than the 
control group, which may indicate protection, as shown 
in cattle and macaques [33–35].
Mycobacterium bovis BCG is more phylogenetically 
related to M. caprae than the “modern” M. tuberculo-
sis strain from which MTBVAC was constructed [36]. 
Testing MTBVAC in large animal models such as goats, 
cattle or pigs may be useful because recent studies in 
Ethiopia and South Africa, where TB is highly prevalent 
in humans, have described several animal cases of M. 
tuberculosis [37–40]. These studies suggest a complex 
epidemiology scenario potentially involving zoonotic 
and anthroponotic TB transmission. In the present study, 
MTBVAC significantly reduced the number of goats with 
extra-pulmonary lesions; BCG vaccines showed a simi-
lar, albeit nonsignificant, trend featuring gross lesions 
restricted mainly to the lungs and pulmonary LNs, as 
previously described in BCG-vaccinated goats [30]. This 
may be quite relevant for identifying vaccines capable of 
protecting against severe primary progressive disease in 
human infants [41]. Nevertheless, 75% of unvaccinated 
goats had extra-pulmonary lesions, and 66.7% had lesions 
in their abdominal organs (data not shown). These lesions 
in the abdomen are difficult to diagnose routinely at the 
slaughterhouse and may also be related to oral infection 
[42].
We evaluated the immunogenicity of MTBVAC and 
BCG vaccines using cellular and humoral techniques 
before exposure to infected donor goats. MTBVAC-
vaccinated animals showed a higher IFN-γ response to 
PPD-B than BCG-vaccinated ones at 1 month post-vac-
cination. This is consistent with a previous study in which 
IFN-γ levels in SO2-vaccinated animals peaked between 
1 and 2  months post-vaccination [18]. In the present 
study, IFN-γ levels remained higher in the MTBVAC 
group than in the BCG group at 3 months post-vaccina-
tion, suggesting long-lasting immunity as described in 
guinea pigs [43].
The E/C cocktail of ESAT-6 and CFP-10 synthetic anti-
gens, which are absent from M. bovis BCG, was devel-
oped as a DIVA for IGRA in cattle [44]. The E/C cocktail 
showed high specificity in BCG-vaccinated cattle, goats 
and sheep [18, 45–47]. In the present study, however, 
higher levels of IFN-γ in response to E/C were observed 
in the MTBVAC group than in the control group at 
1  month post-vaccination, and three positive MTBVAC 
animals were over the cut-off. The MTBVAC and BCG 
groups showed lower rates of sustained conversion in the 
IGRA E/C than the control group, especially at T7 and 
T9. This may reflect sustained M. tuberculosis infection, 
as described in humans after revaccination with BCG 
[48]. It has been suggested that E/C reactivity may be a 
biomarker of protection, as observed in C3H mice vacci-
nated with MTBVAC or with a mutant substrain lacking 
the cfp10 and esat6 genes (MTBVACΔE6C10) [49]. We 
did not observe a correlation between IFN-γ release after 
stimulation with E/C and total lesion score at 1  month 
post-vaccination (T1) and before exposure. A previous 
experiment in cattle described a positive correlation fol-
lowing exposure to infected donors [50] but we only 
observed similar results at the end point analysis.
Since MTBVAC and the SO2 prototype contain the 
RD1 region, which encodes the E/C antigens that are 
responsible for slight IGRA reactivity in animal trials 
[18, 49], new biomarkers are needed as DIVA reagents. 
Alternatively, new cut-offs points should be investigated. 
Data from the first human trial of MTBVAC showed that 
the ELISPOT response of samples from vaccinated indi-
viduals after E/C stimulation was below the cut-off estab-
lished for TB infection [49, 51]. A potential solution may 
be to combine the E/C cocktail with the Rv3615c pep-
tide, shown to act as a DIVA antigen in BGC-vaccinated 
animals [52]. Although Rv3615c is present in the BCG 
genome, it cannot be secreted [53]. Adding the Rv3615c 
peptide to the E/C cocktail increased IGRA sensitiv-
ity from 82 to 90% with samples of naturally-sensitised 
reactor cattle [54]. In our study, 58.3% of infected control 
animals were E/C reactors at the end of the study, and 
this proportion increased to 75% when the response to 
Rv3615c was interpreted in parallel. A similar effect was 
observed with SIT and SCIT tests in cattle [54].
In the present study, the humoral response in unvac-
cinated goats was detected later (4  months post-expo-
sure) than cell-mediated response. Herd testing showed 
higher positivity to P22 ELISA at 2  months after the 
intradermal tests (T5 and T11) than before these tests; 
this positivity was probably boosted by the inoculation 
of intradermal PPDs [55]. Using the P22 ELISA in paral-
lel with cell-mediated techniques allowed detection of all 
infected goats in the control group at the final test point 
as reported in previous studies using unvaccinated ani-
mals [55].
In conclusion, under a natural tuberculosis infection, 
all vaccinated animals showed lesions consistent with TB 
at the end of the study. Nevertheless, both MTBVAC and 
BCG vaccines proved to be immunogenic and effective in 
reducing severity of TB pathology caused by M. caprae. 
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BCG and MTBVAC were associated with similar gross 
lesion scores, so further efficacy studies in large animal 
models evaluating the protection conferred by MTBVAC 
and BCG vaccines against different MTBC species such 
as M. tuberculosis, M. bovis and M. caprae are needed 
in order to elucidate the influence of MTBC species on 
MTBVAC and BCG efficacy. The E/C peptide cocktail 
(IGRA) or protein cocktail (intradermal test) proved to 
be highly specific as DIVA antigens in BCG-vaccinated 
animals, but less sensitive than PPDs. However, a low 
number of MTBVAC-vaccinated goats were positive 
reactors to IGRA stimulated with E/C. The development 
of new biomarkers used as DIVA reagents would facili-
tate the potential implantation of MTBVAC in the future.
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